on-invasive monitoring of airway inflammation in asthmatic patients during adaptation of inhaled steroid therapy

niversity Hospital Antwerp0 个研究点目标入组 40 人开始时间: 2006年1月11日最近更新: 2014年10月7日

适应症

试验速览

暂无简介。

•-Informed consent
•-Male and female patients between 18 and 65 years
•-Established diagnosis of asthma at least 3 months before the start of the study and based on: documented reversible airway obstruction of >= 9% of predicted or documented positive metacholine provocation test
•-Treatment with Symbicort 160/4.5 2*2 during the last 2 months
•-Clinical stable patients with asthma symptoms < 1 a week, no nocturnal symptoms, PEF variability < 20%
•-Patients are able to use Symbicort T (and Bricanyl T) correctly
•-Patients are able to use Peak flow measurements correctly
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

•-Patients with severe cardiovascular disease
•-Recent upper airway infection (within one month before the start of the study)
•-Chronic rhino-sinusitis
•-Use of systemic steroids 30 days before the start of the study
•-Use of ß blocking agents
•-Pregnancy and breast feeding during the study
•-Addiction to alcohol or drugs that may interfere with the overall compliance
•-Planned surgical interventions during the study period
•-Concomitant treatment with anticholinergics, theophyllines and LTRA
•-At visit 2: infections and unstable asthma (symptoms more than 1time a week, nocturnal symptoms, PEF variability of >20%) or upper respiratory tract infection during run-in

发起方

niversity Hospital Antwerp